This report presents the results of the first external quality assessment (EQA) scheme for Bordetella pertussis vaccine antigen expression, pertactin (PRN), pertussis toxin (PT) and filamentous haemagglutinin (FHA) by the European Centre for Disease Prevention and Control (ECDC) as part of the European Reference Laboratory Network for Pertussis (ERLNPert-Net) activities.
The Asian Tiger, Asian Bush and Yellow Fever mosquitos have made themselves at home in Europe throughout the last years, bringing with them some of the more exotic diseases, rarely seen in the EU before.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 12-18 March 2023 and includes updates on COVID-19, iatrogenic botulism, group A streptococcal infection, influenza, chikungunya and dengue, and influenza B among young people.
This evidence brief summarises key issues and priorities for action in Europe and Central Asia on PrEP. It is largely based on data collected between February and August 2022.
Chikungunya is not endemic in the EU/EEA and the majority of the cases are travellers infected outside of the EU/EEA. When the environmental conditions are favourable, in areas where Ae. albopictus is established, viraemic travel-related cases may generate a local transmission of the virus as demonstrated by the sporadic events of chikungunya virus transmission since 2007.
This issue of the Communicable Disease Threats Report (CDTR) covers the period 23-29 January 2023 and includes updates on COVID-19, diphtheriae, influenza, chikungunya, dengue and poliomyelitis.
For 2020, 2 377 malaria cases were reported in the EU/EEA, 2 369 (> 99%) of which were confirmed. Among 2 088 cases with known importation status, 99.8% were travel-related. Five confirmed cases were reported as acquired in the EU (three by France and two by Greece).